Novotech acquires specialty CRO to expand services in Asia-Pacific

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Image Source)
(Image: Getty/Image Source)

Related tags: CRO, Clinical trials

Novotech has acquired a CRO to further support its customers’ clinical research programs across different phases and countries in Asia-Pacific – an area in which it has 10 partnership agreements providing access to more than 1.4bn people.

The Asia-Pacific-based contract research organization (CRO) Novotech ​– with more than 400 staff across Asia-Pacific and business development offices in the US – has acquired Clinical Network Services (CNS), a specialty CRO with more than 140 employees in Australia, New Zealand, and the US.

Novotech CEO Dr. John Moller said, “We increasingly see biopharma companies choosing the Australian market, with its attractive R&D tax structure and world-class medical facilities, to run their first-in-human studies, and then expand up into the Asia region to accelerate the next phases of their programs.”

Moller told us that by joining forces Novotech and CNS can further support biopharma companies’ clinical research programs across different countries and phases.

The deal also allows Novotech to expand its consulting service offering with the CNS “biodesk” capability, he explained.

The biodesk offering provides clients with product development advice at various stages, including toxicology, chemistry, manufacturing, and controls (CMC), as well as regulatory interactions.

“While we are retaining our corporate identities, what the acquisition does mean for biopharma is they now have a proven CRO team to take them through the clinical research phases in the region from Australia and New Zealand to Asia,”​ Moller said. 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more